Blog

NEW YORK, NY / ACCESS Newswire / August 14, 2025 / This month’s United Nations plastics treaty talks have captured global attention. The Guardian, Channel NewsAsia, and Reuters have all highlighted the scale and significance of the negotiations and the complexity of balancing environmental ambition with economic realities. Delegates, industry representatives, NGOs, and policymakers have brought forward deeply held convictions about the best way to protect the planet while preserving livelihoods.

From calls for ambitious production caps and chemical phase-outs to proposals emphasizing voluntary targets and flexibility, each position reflects a personal truth shaped by experience, expertise, and responsibility. These differences are not obstacles to overcome; they are the very fabric of an inclusive global conversation. The opportunity now is to ensure that whatever is decided, every stakeholder can leave the conference confident that progress will be measurable, transparent, and grounded in gains in material efficiency.

SMX (Security Matters) (NASDAQ:SMX) offers a unique and unifying contribution. Rather than advocating for one side of the debate, SMX provides the tools to make any chosen path verifiable and equitable, ensuring that progress is real, recognized, and rewarded while enabling material efficiency to be tracked and proven at every stage of the plastics life cycle.

Building on the Foundation Already Laid

Keep in mind, the treaty discussions are not starting from a blank slate. Every action to date, from scientific research and corporate initiatives to grassroots campaigns, has strengthened the foundation for meaningful change and reinforced the value of material efficiency as a cornerstone of progress.

SMX’s role is to build on and amplify that progress. Its technology embeds invisible, immutable molecular markers into materials at the point of manufacture, creating a secure digital passport that records each material’s origin, composition, and journey from production through use, recovery, and reuse. This technology does more than track; it optimizes reuse, minimizes waste, and delivers measurable gains in material efficiency.

For NGOs such as WWF and the Plastic Pollution Coalition, this means advocacy grounded in verifiable facts. For regulators, it enables unbiased enforcement without adding friction. For brands, it provides proof that sustainability commitments, including gains in material efficiency, are being met. And for the public, it delivers assurance that progress is genuine.

Know this: the power of SMX’s technology is not in replacing what has already been built, but in strengthening its successes and transforming fragmented reporting into a cohesive global network of truth and performance, all made possible by enabling material efficiency. It’s the foundational piece of technology that everyone can use and benefit from. It picks no sides. Instead, it’s a common foundation in a bridge to the next essential step: aligning ambition, accountability, and advantage across all participants.

Aligning Ambition, Accountability, and Advantage

The best news so far is that, regardless of how they plan to achieve it, participants in the treaty talks share a strong commitment to reducing plastic waste, even when their approaches differ. Some countries and organizations prioritize rapid, mandatory cuts, while others focus on scalable, market-driven solutions. Others emphasize scalable, market-driven solutions. Both approaches carry merit, and both deserve a framework that makes results transparent and universally recognized.

SMX can offer that by bridging differing perspectives by adding an economic dimension to verified progress through its Plastic Cycle Token (PCT). When recycled content and responsible practices are authenticated in the SMX system, they are rewarded with measurable, tradable value. These tokens can be used as sustainability credits or converted into direct economic benefit, effectively monetizing gains in material efficiency.

This transforms verification from an administrative requirement into a shared asset. Nations can prove and monetize their circular practices. NGOs can use hard data to encourage further ambition. Businesses can see their sustainability investments directly reflected in market value. And policymakers can uphold treaty commitments with a mechanism that works across diverse economic systems.

Everyone Participates; With SMX, Everyone Wins

Best said, the SMX platform allows every stakeholder to participate in a way that respects their priorities while contributing to a shared global outcome. It does not require compromise on values. Instead, SMX offers a platform where values and material efficiency can be proven, celebrated, and rewarded.

In a week where headlines have focused on the complexity of the treaty process, SMX’s technology offers a timely reminder that solutions exist that honor all perspectives, build on the work already done, and turn intent into measurable, lasting results. This is more than a tool-it is a generational solution capable of equitably resolving debates that have spanned decades. SMX needs no translator, works seamlessly across continents, and thrives in the diversity of opinion the treaty process brings together.

Yes, debates can generate middle ground, but only solutions create outcomes. With that in mind and before the UN adjourns, someone should place a call to SMX. They may find that this debate can be equitably settled, with all sides getting much of what they want.

Sources & References:

• The Guardian, “More than 200 lobbyists at UN’s plastic treaty talks will limit progress, campaigners warn,” Aug. 7, 2025.

• The Guardian, “UN plastic pollution talks must result in ambitious treaty, leading expert says,” Aug. 5, 2025.

• Channel NewsAsia, “UN plastic pollution treaty talks floundering,” Aug. 2025.

• Reuters, “Trump administration memo urges countries reject plastic production caps in UN Treaty,” Aug. 6, 2025.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters)

View the original press release on ACCESS Newswire

Marketing approval allows imminent commercialization of the Colovac device in key EU markets

PARIS, FRANCE AND TAMPA, FL / ACCESS Newswire / August 14, 2025 / SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced that it has been granted European Union marketing approval for its Colovac device under the new Medical Device Regulation (EU MDR 2017/745, Medical Devices, Annex IX Chapter I). This significant milestone confirms the company’s compliance with the EU’s rigorous safety and performance standards, enabling commercial distribution of Colovac across the European Union. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection.^1,2

“This is a pivotal achievement for our company and a testament to the dedication of our regulatory, clinical, and engineering teams,” said Chris Richardson, President and Chief Executive Officer of SafeHeal. “We are now ready to bring the clinical and economic benefits of Colovac to healthcare providers and patients throughout Europe.”

The Colovac endoluminal bypass system is a less-invasive alternative to temporary diverting ostomy, the current standard of care for patients undergoing colorectal resection. Diverting ostomy is applied prophylactically to most patients today undergoing a low anterior resection (LAR) and anastomosis. The ostomy temporarily diverts the stool away from the healing anastomosis to the outside of the body and into an ostomy bag. In most cases, the ostomy is needed only until the anastomosis has healed, and then it can be reversed, typically after 2-6 months. The eventual reversal of the ostomy requires another operation, with a second hospital stay, recovery period and associated complications. In some cases, the ostomy may not be reversed and becomes permanent. In addition to the potential surgical complications associated with ostomy procedures, patients may experience an impact to their quality of life due to social isolation, reduced physical activity and/or intimacy.

Colovac is an alternative to diverting ostomy, designed to eliminate the need for a temporary stoma in most patients. It aims to improve patient recovery and quality of life by eliminating stoma related complications including permanent stoma and eliminating the physical and emotional burden associated with stoma management and care.

“Navigating the MDR process is no small feat for any company, and gaining approval affirms the strength of our technology and the robust data supporting it. After conducting a thorough review of the data supporting the performance and safety of the device and SafeHeal’s quality management system, the EU Medical Device regulators wasted no time in recognizing the obvious clinical benefits Colovac provides to colorectal cancer patients,” said Richardson.

Colovac has been successfully studied in the U.S., Europe, and Asia and the U.S. Food and Drug Administration (FDA) has already granted the product Breakthrough Device Designation. Breakthrough Device designation is granted to novel products and allows FDA to expedite the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.

–

¹ Intended Purpose: The Colovac Anastomosis Protection Device is intended for use in patients requiring low anterior rectal anastomoses to limit stoma creation to only those patients requiring more time for anastomosis healing when the device is removed, allowing patients with a healed anastomosis to avoid stoma creation.

² Indication for Use: The SafeHeal Colovac Device is indicated for use following open, laparoscopic, or robotic-assisted laparoscopic colorectal surgery in patients indicated for diverting ostomy.

###

ABOUT SAFEHEAL®
SafeHeal SAS, headquartered in Paris, France, and its wholly owned U.S. subsidiary, SafeHeal Inc., is a medical device company developing Colovac, a device intended as an alternative to diverting ostomy in patients undergoing colorectal surgery. Colovac is a flexible endoluminal bypass sheath designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for approximately 10 days, until the body’s natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure. In the U.S., Colovac is limited by Federal law to investigational use and not currently available for sale. For more information, please visit www.safeheal.com.

MEDIA CONTACTS
USA
Scott DePierro
Vice President U.S. Operations and Global Business Development, SafeHeal
203-444-0279
sdepierro@safeheal.com
www.safeheal.com

Europe:
Karl-Heinz Blohm
Vice President, International, SafeHeal
+33 (0) 6 5181 7895
kblohm@safeheal.com
www.safeheal.com

SOURCE: SafeHeal

View the original press release on ACCESS Newswire

The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million

Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024

As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US

Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar’s orphan indication products, resulting in non-dilutive funding for Jaguar

REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register

SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported its consolidated second-quarter 2025 financial results.

2025 SECOND QUARTER COMPANY FINANCIAL RESULTS:

• Neonorm^™: Revenues for the non-prescription Neonorm products were minimal for the second quarters of 2025 and 2024.

		Three Months Ending
Financial Highlights		June 30,
(in thousands, except per share amounts)		2025				2024				$ change				% change
Net product revenue		$	2,979			$	2,721				258				9	%
Loss from operations		$	(8,007	)		$	(7,197	)			(810	)			11	%
Net loss attributable to common stockholders		$	(10,406	)		$	(9,492	)			(914	)			10	%
Net loss per share, basic and diluted		$	(10.25	)		$	(2.66	)			(8	)			285	%

• Non-GAAP Recurring EBITDA: Non-GAAP recurring EBITDA for the second quarters of 2025 and 2024 were a net loss of $7.9 million and $8.8 million, respectively.

		Three Months Ending
		June 30,
(in thousands)		2025				2024				$ change				% change
		(unaudited)
Net loss attributable to common stockholders		$	(10,406	)		$	(9,492	)			914				-10	%
Adjustments:
Interest income			(15	)			(108	)			(93	)			86	%
Property and equipment depreciation			16				17				1				4	%
Amortization of intangible assets			427				430				3				1	%
Share-based compensation expense			279				387				109				28	%
Loss on extinguishment of debt			1,822				–				(1,822	)			-100	%
Non-GAAP EBITDA			(7,877	)			(8,766	)			(888	)			10	%

Note Regarding Use of Non-GAAP Measures

The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.

The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar’s performance and provide useful information to investors regarding the Company’s results of operations and financial condition.

Participation Instructions for Webcast

When: Thursday, August 14, 2025 at 8:30 a.m. Eastern

Participant Registration & Access Link: Click Here

Replay Instructions for Webcast

Replay of the webcast on the investor relations section of Jaguar’s website: (click here)

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

About Mytesi^®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Gelclair^®

INDICATIONS

GELCLAIR^® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.

IMPORTANT SAFETY INFORMATION

• Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.

• No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.

• If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.

• If no improvement is seen within 7 days, a physician should be consulted.

You are encouraged to report negative side effects of prescription medical products to the FDA.

Visit www.fda.gov/safety/medwatch, call 1-855-273-0468 or fill-in the form at this link.

Please see full Prescribing Information at:

https://www.gelclairhcp.com/pdf/prescribing-information-instructions-for-use.pdf

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling.Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

See full Prescribing Information at Canalevia.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will hold an investor webcast on August 14, 2025, and statements regarding Jaguar’s planned regulatory pathway to complete a supplemental NDA for crofelemer for patients with metastatic breast cancer. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:
hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Company Reports Quarterly Revenue of $1.2 Million; Net Loss and Loss per Diluted Share of $2.2 Million and $2.13

Quarterly Adjusted EBITDA Loss of $1.7 Million Reflects 40% YOY Improvement

TRNR held 29.6 Million FET tokens as of June 30, 2025 and 67.4 Million FET tokens as of August 13, 2025, with a value in excess of $50 million, representing the largest publicly traded AI-focused Digital Asset Treasury

Stockholders’ Equity Was $16.3 Million at Quarter End

2025 Pro Forma Revenue Guidance Increased to more than $80 Million, driven by Sportstech’s Stronger-Than-Expected Performance, and Fourth Quarter Profitability Guidance Reiterated

AUSTIN, TEXAS / ACCESS Newswire / August 14, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the Wattbike, CLMBR and FORME brands, and the pending acquirer of Sportstech, today announced financial results for its second quarter ended June 30, 2025.

Quarterly Financial Highlights

For the quarter, TRNR reported revenue of $1.2 million, a net loss of $2.2 million – or $2.13 per diluted share – and an Adjusted EBITDA loss of approximately $1.7 million (non‑GAAP).

Results do not include Wattbike (closed July 1, 2025) or Sportstech (pending) for the period. However, if both businesses were included in the second quarter, revenue would have been approximately $17 million.

Digital Asset Treasury Strategy

TRNR also closed a very significant investment in the quarter to begin to execute its Digital Asset Treasury Strategy, and was able to acquire 29.6 million FET tokens by the end of the Q2. TRNR has since completed the cumulative purchase of 67.4 million FET tokens, at an average token price of $0.70, currently worth in excess of $50 million.

Outlook

TRNR is increasing its full‑year 2025 pro forma revenue guidance to more than $80 million, driven by Sportstech’s stronger-than-expected-performance, and by continued momentum across the TRNR + Wattbike platform. TRNR is also reiterating its guidance that it expects to achieve Adjusted EBITDA profitability in the fourth quarter.

Sportstech

The Sportstech acquisition continues to proceed and all parties are working to satisfy the remaining items to close the acquisition and look forward to being able to update investors with more specific guidance on the transaction as soon as possible.

Founder and CEO Trend Ward stated: “We believe that Q2 will be the inflection point for TRNR, as we now have the largest publicly traded AI-focused Digital Asset Treasury, comprised of 67.4 million FET tokens, worth more than $50 million, and we are increasing our 2025 pro forma revenue guidance to more than $80 million, driven by the stronger-than-expected performance of Sportstech, our pending acquisition. We closed the Wattbike acquisition right after the quarter had ended and all parties are working on completing the remaining items to close the Sportstech acquisition as soon as we can. If both acquisitions were included in the second quarter, we would have generated approximately $17 million in revenue for the quarter. We are also reiterating that we expect to be profitable in the fourth quarter. In our view, the combination of these synergistic acquisitions, along with our AI-focused Digital Asset Treasury, represents a significant opportunity for investors.”

For more commentary, information and details of TRNR’s strategy, as well as to sign up for direct updates, see the Company’s investor website, latest FAQs and required filings with the US Securities & Exchange Commission (SEC).

TRNR Investor Contact
ir@interactivestrength.com

About Interactive Strength Inc.:

Interactive Strength Inc. (NASDAQ:TRNR) has established a leading portfolio of premium fitness brands-Wattbike, CLMBR, and FORME-that combine advanced hardware, smart technology, and immersive content to deliver exceptional training experiences for both commercial and home use.

• Wattbike offers a range of high-performance indoor bikes that set the global standard in cycling. Known for unmatched accuracy, realistic ride feel, and advanced performance tracking, Wattbike is trusted by elite athletes, national teams, and fitness enthusiasts around the world.

• CLMBR redefines the next-generation vertical climbing experience through its patented open-frame design and immersive touchscreen, delivering a high-intensity, low-impact workout that’s both efficient and effective.

• FORME delivers strength, mobility, and recovery training through immersive content, performance-grade hardware, and expert coaching. Its wall-mounted systems include the Studio, a smart fitness mirror for guided programming and live 1:1 personal training, and the Lift, which adds smart resistance cable training-ideal for high-performance environments and sport-specific development.

From elite performance to everyday wellness, our ecosystem of performance-focused solutions delivers data-driven outcomes for athletes, fitness enthusiasts, and commercial operators.

• Adjusted EBITDA is widely used by investors and securities analysts to measure a company’s operating performance without regard to items such as stock-based compensation expense, depreciation and amortization expense, other expense (income), net, and provision for income taxes that can vary substantially from company to company depending upon their financing, capital structures, and the method by which assets were acquired;

• Our management uses Adjusted EBITDA in conjunction with financial measures prepared in accordance with GAAP for planning purposes, including the preparation of our annual operating budget, as a measure of our core operating results and the effectiveness of our business strategy, and in evaluating our financial performance; and

• Adjusted EBITDA provides consistency and comparability with our past financial performance, facilitate period-to-period comparisons of our core operating results, and may also facilitate comparisons with other peer companies, many of which use similar non-GAAP financial measures to supplement their GAAP results.

• Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;

• Adjusted EBITDA excludes stock-based compensation expense, which has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy;

• Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) interest expense, or the cash requirements necessary to service interest or principal payments on our debt, which reduces cash available to us; or (3) tax payments that may represent a reduction in cash available to us;

• Adjusted EBITDA does not reflect impairment charges for fixed assets and capitalized content, and gains (losses) on disposals for fixed assets;

• Adjusted EBITDA does not reflect (gains) losses associated with debt extinguishments.

• Adjusted EBITDA does not reflect losses associated with vendor settlements.

• Adjusted EBITDA does not reflect transaction related expenses for CLMBR acquisition and pending acquisitions of Wattbike and Sportstech.

• Adjusted EBITDA does not reflect non cash fair value gains (losses) on convertible notes, derivatives, warrants and unrealized currency gains (losses).

Forward Looking Statements:

This press release includes certain statements that are “forward-looking statements” for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements generally are accompanied by words such as “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the value or potential opportunity of the digital asset treasury strategy, its value staying above $50 million, the possibility of acquiring future businesses or completing the referenced pending transactions in a timely manner or at all, the financial performance of those acquisitions and the resulting guidance of having more than $80m of pro forma revenue in 2025, achieving profitability by Q4, and the financial performance of the acquisition targets which have not been audited or reviewed by a PCAOB auditor and could vary materially (a) once that audit or review work is completed and such financials are included in the Company’s reported financials and (b) due to the effect of the exchange rates of foreign currencies which can be volatile, or that the business is at an inflection point in Q2 and that there is a significant opportunity for investors. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Risks and uncertainties include but are not limited to: demand for our products and the products of the acquisition targets if the acquisitions are completed (collectively, the “Products”); competition, including technological advances made by and new products released by our competitors and the competitors of the acquisition targets; our ability to accurately forecast consumer demand for our Products and adequately maintain our inventory; and our reliance on a limited number of suppliers and distributors for our Products. A further list and descriptions of these risks, uncertainties and other factors can be found in filings with the Securities and Exchange Commission. To the extent permitted under applicable law, the Company assumes no obligation to update any forward-looking statements.

# # #

SOURCE: Interactive Strength Inc.

View the original press release on ACCESS Newswire

Providing high-fidelity, live mission training capabilities for advanced weapons and tactics training

SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 14, 2025 / Cubic Defense, the world’s leading provider of advanced air combat training, announces the IDIQ contract award by the USAF for activities relating to the procurement, integration, deployment and sustainment of the entire P5 Combat Training Systems (P5CTS) inventory.

“Our P5CTS is designed to provide users with live mission training capabilities for advanced weapons and tactics training,” stated Russ Marsh, President, Cubic Defense. “The system features real-time air-to-air and air-to-ground weapons simulations and live monitoring capabilities. With the recent addition of the P5 Security Subsystem Upgrade (P5 SSU) to enable fully interoperable encrypted Time Space Position Information with Coalition 5^th Generation aircraft, Cubic and its partners are continuing to invest and deliver upgrades to the P5 CTS infrastructure to preserve customer investments in authentic training.”

QATAR. 11.28.2023. Photo by Staff Sgt. Daniel Hernandez, USAF. DVIDS – Images –
Qatar Emiri Air Force F-15E Strike Eagles participate in Exercise Sky Shield.
Cubic’s P5 Combat Training System (P5CTS) seen under the wing.

Cubic, along with its principal subcontractor, Leonardo DRS, will be supporting all contractor activities relating to the procurement, integration, deployment, and sustainment. The P5CTS improves U.S. and coalition training used by the USAF, US Marine Corps, US Navy and coalition partners. The system permits the user to continuously relay time, space, position information (TSPI) of the aircraft during training exercises, allowing the warfighter to train as they fight on a common platform with coalition partners.

About Cubic

Cubic creates and delivers technology solutions in transportation that make people’s lives easier by simplifying their daily journeys, and defense capabilities that help promote mission success and safety for those who serve their nation. Led by our talented teams around the world, Cubic is driven to solve global challenges through innovation and service to our customers and partners.

Part of Cubic’s portfolio of businesses, Cubic Defense provides networked Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance and Reconnaissance (C5ISR) products and services and is a leading provider of live, virtual, constructive, and game-based training solutions for both U.S. and Allied Forces. These mission-inspired capabilities enable assured multi-domain access; converged digital intelligence; and superior readiness for defense, intelligence, security and commercial missions. For more information, visit: Cubic Defense.

Media Contacts:
Geri MacDonald
Cubic Defense
geri.macdonald@cubic.com

Touchdown PR for Cubic Defense:
Cubicdefense@touchdownpr.com

SOURCE: Cubic Defense

View the original press release on ACCESS Newswire

Comparable clinic revenues increase 5.7% vs prior year period

Net losses decrease 10% vs. prior year period

VIRGINIA BEACH, VA / ACCESS Newswire / August 14, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today reported financial results for the second quarter ended June 30, 2025.

Second Quarter 2025 Financial Highlights Compared to Prior Periods

• Total revenue of approximately $4.3 million, a sequential increase of 20% from Q1 2025 and a decrease of 2% from the prior year period. The decrease in revenue is attributed to the exclusion of the Hawaii clinic (KVC) from 2025 results

• Services revenue of approximately $3.2 million, a sequential increase of 17% from Q1 2025 and a decrease of 1% from the prior year period

• Product revenue of $1.1 million, a sequential increase of 21% from Q1 2025 and a decrease of 7% from the prior year period

• Comparable clinic revenues increased 5.7% from the prior year period

• Total operating expenses of $6.2 million, an increase of 5% from the prior year period

• Net loss of $3.0 million, a decrease of $0.4 million from the prior year period

• Entered an exclusive, non-binding Letter of Intent to acquire 100% ownership interest in one animal hospital located in New Jersey. Once completed, the acquisition could potentially add up to approximately $2.0 million in (unaudited) revenue

• Entered into a securities purchase agreement for the issuance and sale of securities for up to $10M under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share

• Announced the launch of a company-wide incentive and recognition program, which provides vital new engagement tools and offers new avenues to wealth for all employees across their clinic network

• Integrated a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into the Company’s medical software. The Company believes this is the only AI platform being offered among publicly traded veterinary clinic networks

• Acquired 100% ownership interest in one animal hospital located in central Florida (DeBary). The acquisition is expected to add up to approximately $1.8 million in (unaudited) revenue, and brings the Company’s Florida holdings up to 5 clinics

• For the second quarter of 2025, total revenue was approximately $4.3 million, a decrease of 2% from the prior year period but an increase of 20% from Q1 2025. Comparable clinic revenues increased 5.7% from the prior year period.

Second Quarter 2025 Operational Highlights

• Entered an exclusive, non-binding Letter of Intent to acquire 100% ownership interest in one animal hospital located in New Jersey. Once completed, the acquisition could potentially add up to approximately $2.0 million in (unaudited) revenue

• Entered into a securities purchase agreement for the issuance and sale of securities for up to $10M under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share

• Announced the launch of a company-wide incentive and recognition program, which provides vital new engagement tools and offers new avenues to wealth for all employees across their clinic network

• Integrated a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into the Company’s medical software. The Company believes this is the only AI platform being offered among publicly traded veterinary clinic networks

• Acquired 100% ownership interest in one animal hospital located in central Florida (DeBary). The acquisition is expected to add up to approximately $1.8 million in (unaudited) revenue, and brings the Company’s Florida holdings up to 5 clinics

Executive Commentary

“During the second quarter of 2025, we started to see the rewards of our new initiatives, processes, and hard work over the past 18 months with sequential revenue growth of 20% and year over year organic growth of 5.7%.,” said Kimball Carr, Inspire ‘s Chairman, President and Chief Executive Officer. “We also grew our portfolio of clinics to 14 with the recently announced acquisition in Florida while significantly improving our liquidity and capital structure with the recently announced preferred stock transaction. I believe this quarter will mark the turning point for our business model and that our top line growth will accelerate going forward.

Second Quarter 2025 Financial Overview

All comparisons are made relative to the same period in 2024 unless otherwise stated.

• Net loss for the first quarter of 2025 decreased $352,000, or 10%, to $3.0 million. The decline in net loss is primarily attributable to the reduction of interest expense and the exclusion of the operating expenses associated with KVC.

Balance Sheet

As of June 30, 2025, the Company had cash and cash equivalents of approximately $0.2 million.

About Inspire Veterinary Partners, Inc.

Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.

For more information, please visit: www.inspirevet.com.

Connect with Inspire Veterinary Partners, Inc.

Facebook

https://www.facebook.com/InspireVeterinaryPartners/

LinkedIn

https://www.linkedin.com/company/inspire-veterinary-partners/

Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding management’s expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption “Risk Factors” in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Investors
CoreIR
516-386-0430

General Inquiries
Morgan Wood
Mwood@inspirevet.com

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Balance Sheet

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Operation

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Cash Flows

SOURCE: INSPIRE VETERINARY PARTNERS, INC.

View the original press release on ACCESS Newswire

• Exclusive Letter of Intent for West Coast distribution of Nimbus Boats USA

• Expands Nautical Ventures’ lineup with premium Scandinavian‑designed models

• Strategic step to broaden Vision Marine’s portfolio after acquiring Nautical Ventures

• Enhances choice and experience for boaters in Florida’s top market

FORT LAUDERDALE, FL / ACCESS Newswire / August 14, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a leader in premium on‑water experiences and the owner of Florida‑based dealership network Nautical Ventures, today announced that Nautical Ventures has entered into a Letter of Intent with Nimbus Boats USA to exclusively distribute Nimbus powerboats on Florida’s West Coast.

Nimbus’s Tender, Commuter, Weekender and Coupe series are recognized worldwide for their Scandinavian design, versatile layouts and meticulous construction. With more than seventy years of heritage, Nimbus is one of the respected powerboat builders in Europe and North America, and the largest Scandinavian boat builders by volume. Upon entering into definitive agreements, which the parties expect to conclude by March 31, 2026, Nautical Ventures would be authorized to promote, sell and service these models in Florida’s West Coast region beginning August 1, 2025.

“Adding Nimbus to our lineup will be a strategic move to broaden our product portfolio and serve customers who are seeking premium day‑cruiser and weekender boats,” said Alexandre Mongeon, Co‑Founder and Chief Executive Officer of Vision Marine. “Our vision is to curate the best selection of boats on the market and deliver an elevated on‑water experience. This partnership will expand our reach in Florida, leverage the sales and service capabilities of Nautical Ventures and align with our plan to build a diversified portfolio that addresses high‑margin segments. We believe it will position us to capitalize on strong consumer demand and favourable market trends, while continuing to support and grow our existing brand relationships.”

Industry data underpins the commercial rationale for the partnership. Boating and fishing contribute roughly $1.2 trillion to the U.S. outdoor recreation economy and support more than 812,000 jobs [1]. Florida is the largest market for new powerboats, engines and accessories, generating $6.4 billion in sales in 2023, a 3.1 percent increase over the prior year [2]. The National Marine Manufacturers Association projects that new powerboat sales will rebound in 2025, with total boating expenditures expected to rise 3-5 percent above 2024’s record levels [3]. Adventure‑style boats-versatile models designed for day trips, water sports and island hopping-are among the fastest‑growing categories in recreational boating, and Nimbus’s Tender, Commuter, Weekender and Coupe series are squarely in this segment. These trends suggest a sizable and resilient addressable market for high‑quality day boats and weekenders [4].

[1] https://www.bea.gov/
[2] www.marinadockage.com/
[3] https://boatingindustry.com/
[4] U.S. boating and outdoor recreation statistics sourced from the National Marine Manufacturers Association and the U.S. Bureau of Economic Analysis. See NMMA press release “Innovation Driving U.S. Boat Sales Demand As Key Winter Boat Show Buying Season Gets Underway” (https://www.nmma.org/press/article/24937) and Boating Industry article “NMMA shares 2024 U.S. boat sales stats” (https://boatingindustry.com/news/2025/01/14/nmma-shares-2024-u-s-boat-sales-stats/) for projections on powerboat sales. Adventure‑style boat trend commentary reflects general market observations and is not tied to a specific citation.

The Nimbus partnership is one of several initiatives Vision Marine is pursuing as it structures and expands its brand portfolio under new leadership. In June 2025, the Company acquired Nautical Ventures, a Florida‑based recreational boat dealership, marina and service provider widely recognized as one of the top networks in the United States and the number‑one Axopar dealership worldwide. Nautical Ventures operates nine high‑volume retail locations across Florida and distributes a diverse range of premium brands- including Axopar, Beneteau, Brabus, Edgewater, Highfield, NorthStar, Smokercraft, Wellcraft -serving customers from pontoons to luxury yacht owners. The acquisition created North America’s first electric boat propulsion and multi‑brand retail company, combining Vision Marine’s high‑voltage E‑Motion™ powertrain and electric boats with Nautical Ventures’ established sales and service infrastructure. Integrating Nimbus into this platform is part of a broader strategy to offer consumers the best products across propulsion types while supporting long‑term growth for all brands in the Nautical Ventures family.

About Vision Marine

Vision Marine Technologies Inc. (NASDAQ:VMAR) is a leader in high‑performance electric propulsion systems and premium boating experiences. The Company’s proprietary E‑Motion™ 180 horsepower electric outboard is the first high‑voltage system purpose‑built for the marine industry. In June 2025 Vision Marine acquired Nautical Ventures, creating North America’s first electric propulsion and multi‑brand boat retail company. The combined entity operates nine retail locations across Florida and distributes a wide range of prestigious boating brands. By uniting advanced technology with established sales and service infrastructure, Vision Marine aims to accelerate adoption of cleaner, high‑performance boating and provide consumers with an unmatched on‑water experience.

About Nimbus Boats USA

Nimbus Boats USA is the American arm of Nimbus Group, a global leader in the design and manufacture of luxury powerboats. With more than seventy years of heritage, Nimbus has earned a reputation for quality, safety, and innovation, and is the largest Scandinavian boat builder by volume. Its award-winning Tender, Commuter, Weekender, and Coupe series are sold through an extensive international dealer network spanning more than fifty countries. [5].

[5] Nimbus Boats USA information derived from company disclosures and publicly available sources, including Nimbus Group corporate materials.

Forward‑Looking Statement

Certain statements in this press release may constitute “forward‑looking statements” within the meaning of U.S. federal securities laws. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward‑looking statements include, among others, statements regarding the expected terms and timing of the definitive distribution agreement with Nimbus Boats USA, anticipated benefits of the partnership, projected market opportunities and Vision Marine’s strategic outlook. Factors that could affect actual results are detailed in the “Risk Factors” section of Vision Marine’s filings with the U.S. Securities and Exchange Commission. Vision Marine undertakes no obligation to update or revise any forward‑looking statements, except as required by law.

Investor and Company Contact:
Bruce Nurse
Investor Relations
(303) 919‑2913
bn@v‑mti.com

SOURCE: Vision Marine Technologies Inc

View the original press release on ACCESS Newswire

WATERLOO, ON / ACCESS Newswire / August 14, 2025 / CryoDragon Inc., a boutique creative studio based in Kitchener-Waterloo, has won the 2026 Consumer Choice Award in the Web Design category for the Waterloo Region. Known for delivering personalized, scientifically-informed digital solutions, the award highlights CryoDragon’s commitment to crafting responsive, accessible websites and robust branding packages that help clients across Canada stand out.

Since launching in 2015, CryoDragon has built a reputation for offering full-service web design, e-commerce development, AODA-compliant accessibility solutions, SEO optimization, and comprehensive branding support – from logo design to photography and scientific illustration. Their services are delivered entirely in-house by Craig Christoff and Brenda Lee, a husband-and-wife team that uses a wealth of knowledge and expertise from their experiences to ensure clients receive expert oversight and a consistent creative vision.

Custom Websites Tailored to Real Needs

CryoDragon designs and develops websites tailored to client goals – ranging from lead generation and brand storytelling to e-commerce sales and membership portals. Each project includes consultation, user-experience design, coding, content strategy, hosting, and maintenance. The studio’s hands-on, data-driven process helps businesses improve site traffic, engagement, and conversions.

“We don’t outsource anything,” says Craig. “Everything stays under our roof, ensuring quality, seamless communication, and no hidden costs.”

SEO, Accessibility & Ongoing Support

CryoDragon offers AODA-compliant website design, incorporating accessibility (WCAG 2.0 A-AAA), SEO enhancements, content planning, and post-launch monitoring. Their long-term hosting and maintenance packages include analytics reporting and timely updates to keep sites secure and optimized.

A Branding & Design Partner Across Industries

Beyond web work, CryoDragon provides cohesive branding solutions – logo creation, corporate print design, photography, videography, and scientific illustrations. Their clients range from local startups and nonprofits to national consultants, research institutions, and corporate enterprises.

Regional Reach, National Impact

While based in Kitchener-Waterloo, CryoDragon has completed projects throughout Southwestern Ontario (Guelph, Cambridge, Hamilton) and across Canada – from Vancouver to Halifax. Their client roster includes the Biophysical Society of Canada, StrongPoint Automation, and HP Gas MRI Lab.

Clients praise their responsive communication, attention to detail, and professionalism:

“CryoDragon is a rare company… informative, highly responsive, incredibly patient and charitable… we gained a partner.” – Argus

“Prompt and professional… delivered on time… outstanding work and commitment.” – Biophysical Society of Canada

Trusted & Accredited Studio

CryoDragon is accredited by the Better Business Bureau with an A+ rating, reflecting its commitment to trust and transparency. Their Consumer Choice Award win further validates their excellence in client satisfaction, service quality, and local reputation – selected through an independent research process that includes customer surveys and brand reputation analysis. Their small-team approach makes them flexible, affordable, and deeply invested in each client’s success.

Commitment That Fuels Creativity

This award reflects CryoDragon’s dedication to delivering creative excellence, scientific rigor, and client-focused service. Their responsive design, accessible builds, and brand strategy help businesses thrive online, while their honest pricing and strong communication build lasting relationships.

“We view every project as a partnership,” says Brenda Lee. “We bring creativity, technical skill – and genuine care – to help your brand stand out.”

To learn more about CryoDragon’s award-winning digital and branding services, visit cryodragon.ca or explore their CCA Profile.

About CryoDragon Inc.
Founded in 2015, CryoDragon is a full-service creative studio based in Kitchener-Waterloo, with services across Southwestern Ontario and Canada. The in-house team offers website design and development, e-commerce, SEO, AODA-compliant accessibility, branding, graphic design, photography, videography, and scientific illustration – all driven by data and creative thinking. Accredited by the BBB with an A+ rating.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire